鲁索替尼乳膏(Opzelura)在哪买比较靠谱？

Introduction: Ruxolitinib cream (Opzelura) is the first drug approved by the FDA to treat pigmentation in patients with vitiligo. Ruxolitinib cream is applied twice daily to the affected area accounting for 10% of the body surface area. Patients may need to use ruxolitinib cream for more than 24 weeks to obtain satisfactory results.

Where to buy ruxolitinib cream (Opzelura) more reliably

When purchasing, it is very important to choose formal and reliable channels. The following are some recommended purchasing methods.

1. Hospital pharmacies: ruxolitinib cream (Opzelura) has been launched in the Greater Bay Area and Macau in China. Patients can go to large hospitals in the above areas for treatment, and then purchase it directly at the pharmacies of local hospitals.

2. Online pharmacies: Some reputable online pharmacies provide purchase services for ruxolitinib cream (Opzelura) and can mail the medicine directly to patients.

3. Physical pharmacies: Ruxolitinib cream (Opzelura) can usually be purchased in local pharmacies in areas where it is marketed. A medical prescription is required before purchase.

4. Medical service institutions: Patients can also purchase ruxolitinib cream, including the original version or the generic version, through domestic medical service institutions.

When purchasing ruxolitinib cream, you need to carefully choose legal and trustworthy channels. Before purchasing ruxolitinib cream or any other medicine, it is recommended to consult a doctor or pharmacist to ensure that it is suitable for your condition and to obtain correct dosage instructions. Also, make sure you understand the side effects and precautions of the medication to ensure safe use.

Serious side effects of Ruxolitinib Cream (Opzelura)

If the following serious side effects occur, you need to seek medical treatment immediately.

1. Severe eye symptoms, such as sudden vision loss, blurred vision, narrow field of vision, eye pain or swelling, or seeing halos around lights.

2. Severe heart symptoms, such as fast, irregular or rapid heartbeat, chest shaking, shortness of breath, sudden dizziness, palpitations or fainting.

3. Severe headache, confusion, slurred speech, weakness in arms or legs, difficulty walking, loss of coordination, feeling unsteady, muscle stiffness, high fever, heavy sweating, or tremors.

The efficacy and safety of ruxolitinib cream

have been confirmed in two clinical trials, NCT04052425 and NCT04057573. In both trials, subjects with non-segmental vitiligo were randomly assigned to receive ruxolitinib cream or placebo cream twice daily for 24 weeks, after which all subjects received ruxolitinib cream for an additional 28 weeks.

At the end of the 24-week treatment period, 30% of patients treated with ruxolitinib cream had at least a 75% improvement in the facial vitiligo area score index, compared with only 10% of placebo patients.

When ruxolitinib cream is used to treat vitiligo, the recommended dose is to apply a thin layer to the affected area twice daily, up to 10% of the body surface area. If you want to achieve better results, you may need to treat it for more than 24 weeks. If the patient does not notice repigmentation of the lesion within 24 weeks, the patient should seek medical attention for re-evaluation.